"CREB-Binding Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the p300-CBP transcription factor family that was initially identified as a binding partner for CAMP RESPONSE ELEMENT-BINDING PROTEIN. Mutations in CREB-binding protein are associated with RUBINSTEIN-TAYBI SYNDROME.
MeSH Number(s)
D08.811.913.050.134.440.249
Concept/Terms
CREB-Binding Protein- CREB-Binding Protein
- CREB Binding Protein
- Nuclear Protein CBP
- CBP, Nuclear Protein
- Phospho-CREB-Binding Protein
- Phospho CREB Binding Protein
Below are MeSH descriptors whose meaning is more general than "CREB-Binding Protein".
Below are MeSH descriptors whose meaning is more specific than "CREB-Binding Protein".
This graph shows the total number of publications written about "CREB-Binding Protein" by people in Harvard Catalyst Profiles by year, and whether "CREB-Binding Protein" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 4 | 4 |
| 1998 | 0 | 7 | 7 |
| 1999 | 0 | 8 | 8 |
| 2000 | 0 | 12 | 12 |
| 2001 | 0 | 11 | 11 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 4 | 4 |
| 2004 | 0 | 4 | 4 |
| 2005 | 2 | 3 | 5 |
| 2006 | 1 | 1 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 3 | 5 | 8 |
| 2010 | 1 | 4 | 5 |
| 2011 | 5 | 0 | 5 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 2 | 1 | 3 |
| 2016 | 3 | 1 | 4 |
| 2017 | 3 | 1 | 4 |
| 2018 | 3 | 0 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2023 | 0 | 3 | 3 |
Below are the most recent publications written about "CREB-Binding Protein" by people in Profiles.
-
Comparative Analysis of Drug-like EP300/CREBBP Acetyltransferase Inhibitors. ACS Chem Biol. 2023 10 20; 18(10):2249-2258.
-
ß-catenin/CBP activation of mTORC1 signaling promotes partial epithelial-mesenchymal states in head and neck cancer. Transl Res. 2023 10; 260:46-60.
-
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leuk Lymphoma. 2023 03; 64(3):738-741.
-
NF-?B suppression synergizes with E7386, an inhibitor of CBP/ß-catenin interaction, to block proliferation of patient-derived colon cancer spheroids. Biochem Biophys Res Commun. 2022 01 01; 586:93-99.
-
Discovery of spirohydantoins as selective, orally bioavailable inhibitors of p300/CBP histone acetyltransferases. Bioorg Med Chem Lett. 2021 05 01; 39:127854.
-
Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. Cell Chem Biol. 2021 04 15; 28(4):503-514.e12.
-
SATB2 drives glioblastoma growth by recruiting CBP to promote FOXM1 expression in glioma stem cells. EMBO Mol Med. 2020 12 07; 12(12):e12291.
-
Structure-based drug optimization and biological evaluation of tetrahydroquinolin derivatives as selective and potent CBP bromodomain inhibitors. Bioorg Med Chem Lett. 2020 11 15; 30(22):127480.
-
Design, synthesis, and biological evaluation of tetrahydroquinolin derivatives as potent inhibitors of CBP bromodomain. Bioorg Chem. 2020 08; 101:103991.
-
Interaction between the scaffold proteins CBP by IQGAP1 provides an interface between gene expression and cytoskeletal activity. Sci Rep. 2020 04 01; 10(1):5753.